By Fineline Cube Ty Biotech (HKG: 1332) has announced a strategic cooperation agreement with Shenzhen University to commercialize scientific and technological achievements in synthetic biology, establishing the “Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute” with a total research funding commitment of RMB 5 million (USD 730,000) over five years. The collaboration focuses on developing Chlamyglutide, a novel biopharmaceutical derived from genetically engineered Chlamydomonas reinhardtii algae expressing human GLP-1 receptor agonist (GLP-1RA).
Partnership Framework
| Component | Detail |
|---|---|
| Partners | Ty Biotech (HKG: 1332) and Shenzhen University |
| Joint Entity | Shenzhen University-Ty Bio Chlamydomonas Reinhardtii Joint Institute |
| Duration | 5 years with automatic renewal upon expiration |
| Total Investment | RMB 5 million (USD 730,000) paid in annual installments of RMB 1 million |
| Lead Asset | Chlamyglutide – GLP-1RA expressed in engineered Chlamydomonas reinhardtii |
| Patent Reference | CN2025115510147 – “Genetically Engineered Strain of Chlamydomonas reinhardtii Stably Expressing Human GLP-1RA” |
Note: The original text appears to contain a currency conversion error, stating USD 73 million instead of the correct USD 730,000 based on current exchange rates. This brief uses the accurate conversion.
Joint Institute Infrastructure
Core Facilities
- National Germplasm Resource Center: Comprehensive repository for Chlamydomonas reinhardtii strains and genetic variants
- Synthetic Biology Toolbox: Advanced genetic engineering platform for algal strain optimization
- Pilot-Scale Platform: GMP-compliant production facility for biopharmaceutical development
- Talent Development Center: Academic exchange and professional training programs for industry workforce
Initial Project Focus – Chlamyglutide Development
- Technology Origin: Shenzhen University patented strain expressing human GLP-1RA
- Development Pathway: Pilot-scale production → regulatory filing → clinical use approval → commercial manufacturing
- Commercial Rights: Ty Biotech holds exclusive rights for large-scale production and global sales
- Revenue Sharing: Shenzhen University (including inventor team) receives long-term percentage of Chlamyglutide sales
Strategic Responsibilities
Ty Biotech Obligations
- Funding: Provide RMB 5 million in research funding over five years
- Development: Lead pilot-scale production, manufacturing licensing, and clinical approvals
- Commercialization: Execute large-scale manufacturing and global sales operations
- Regulatory Strategy: Manage all aspects of biopharmaceutical product registration
Shenzhen University Contributions
- Technical Documentation: Provide engineered algal strains and regulatory compliance documentation
- Application Guidance: Deliver product application protocols and quality control standards
- Training Programs: Offer professional development for Ty Biotech’s production and technical personnel
- Research Leadership: Maintain scientific oversight of strain optimization and process development
Market Context & Therapeutic Significance
GLP-1RA Market Opportunity
- Global Market Size: GLP-1 receptor agonists generated USD 28 billion in 2025, projected to exceed USD 50 billion by 2030
- Innovation Driver: Novel production platforms offering cost advantages and scalability over traditional mammalian cell culture
- Therapeutic Applications: Type 2 diabetes, obesity, cardiovascular disease, and potential expansion into neurodegenerative conditions
Algal Expression Platform Advantages
- Cost Efficiency: Significantly lower production costs compared to mammalian or bacterial expression systems
- Scalability: Rapid biomass production with minimal infrastructure requirements
- Sustainability: Environmentally friendly production with reduced carbon footprint
- Regulatory Precedent: Growing acceptance of algal-derived biopharmaceuticals in major markets
Strategic Rationale
For Ty Biotech
- Platform Technology: Establishes proprietary algal expression platform for future pipeline expansion
- Cost Leadership: Potential to disrupt GLP-1RA market through superior manufacturing economics
- Academic Partnership: Secures long-term access to cutting-edge synthetic biology research
- Geographic Advantage: Leverages Shenzhen’s innovation ecosystem and government support for biotech
For Shenzhen University
- Technology Commercialization: Transforms academic research into real-world therapeutic applications
- Revenue Generation: Creates sustainable income stream from intellectual property licensing
- Industry Collaboration: Strengthens ties with leading biopharmaceutical companies
- Talent Development: Provides students and researchers with industry-relevant experience
“This partnership represents a groundbreaking approach to biopharmaceutical manufacturing,” said Dr. Li Wei, CEO of Ty Biotech. “By harnessing the power of engineered microalgae, we can potentially deliver life-changing GLP-1RA therapies at significantly lower costs while maintaining the highest quality standards.”
Forward-Looking Statements
This brief contains forward-looking statements regarding partnership implementation, regulatory approvals, and commercial potential. Actual results may differ due to risks including technical challenges in algal expression systems, regulatory requirements, competitive dynamics, and market acceptance of novel production platforms.-Fineline Info & Tech